












# Ciron Drugs & Pharmaceuticals Pvt. Ltd.

N-118,119,113,119/1,119/2 & 118/1, M.I.D.C., Tarapur,  
Boisar, Dist. Palghar - 401 506.

Item Description	Carton	Artwork Number	N/A
Product Name	MYTAR (Mupirocin Ointment BP 2% w/w)	Customer / Country	Chez Pharma
Artwork Code	N/A	Pack Size	15g
Substrate Specification	300 GSM ITC Cyber XL BOARD	Pharmacode / Barcode	N/A
Minimum Font Size	4 pt	Dimension	115 x 25 x 21 mm
Colour Scheme (Pantone Number)	Cyan  Magenta  Yellow	Artist Name	Pritesh
	Black  PANTONE 287 C  PANTONE 7579 C	Language	English
Subject	N/A	Date	10-04-2023
Reason For Revision	N/A	Printer Name	



		<b>Ciron Drugs &amp; Pharmaceuticals Pvt. Ltd.</b> N-118,119,113,119/1,119/2 & 118/1, M.I.D.C., Tarapur, Boisar, Dist. Palghar - 401 506.	
Item Description	Tube	Artwork Number	N/A
Product Name	MYTAR (Mupirocin Ointment BP 2% w/w)	Customer / Country	Chez Pharma
Artwork Code	N/A	Pack Size	15g
Substrate Specification	N/A	Pharmacode / Barcode	N/A
Minimum Font Size	5 pt	Dimension	Dia 19 x 100mm
Colour Scheme (Pantone Number)	 Cyan  Magenta  Yellow	Artist Name	Pritesh
	 Black  PANTONE 287 C  PANTONE 7579 C	Language	English
Subject	N/A	Date	10-04-2023
Reason For Revision	N/A	Printer Name	



ø19x100mm  
 15g, ø19x100mm



# Ciron Drugs & Pharmaceuticals Pvt. Ltd.

N-118,119,113,119/1,119/2 & 118/1, M.I.D.C., Tarapur,  
Boisar, Dist. Palghar - 401 506.

Item Description	Leaflet	Artwork Number	N/A
Product Name	MYTAR (Mupirocin Ointment BP 2% w/w)	Customer / Country	Chez Pharma
Artwork Code	N/A	Pack Size	15g
Substrate Specification	N/A	Pharmacode / Barcode	N/A
Minimum Font Size	5.5 pt	Dimension	90 x 130 mm
Colour Scheme (Pantone Number)	■ Black	Artist Name	Pritesh
		Language	English
Subject	N/A	Date	10-04-2023
Reason For Revision	N/A	Printer Name	

90 mm  
Front

Back

## MYTAR

### Mupirocin Ointment BP 2% w/w

#### Composition:

Each gram contains:  
Mupirocin BP 2% W/W

#### Pharmacological properties

#### Pharmacokinetic properties:

Mupirocin is a novel antibiotic. After topical application of Mupirocin Ointment, mupirocin is only very minimally absorbed systemically and that which is absorbed is rapidly metabolised to the antimicrobially inactive metabolite, monic acid. Penetration of mupirocin into the deeper epidermal and dermal layers of the skin is enhanced in traumatised skin and under occlusive dressings.

Elderly:

No restrictions unless there is evidence of moderate or severe renal impairment

#### Pharmacodynamic properties

Pharmacotherapeutic group: Antibiotics and chemotherapeutics for topical use,

ATC code: D06AX09

#### Mechanism of action

Mupirocin is a novel antibiotic produced through fermentation by *Pseudomonas fluorescens*. Mupirocin inhibits isoleucyl transfer-RNA synthetase, thereby arresting bacterial protein synthesis. Mupirocin has bacteriostatic properties at minimum inhibitory concentrations and bactericidal properties at the higher concentrations reached when applied locally.

#### Mechanism of Resistance

Low-level resistance in staphylococci is thought to result from point mutations within the usual staphylococcal chromosomal gene (ileS) for the target isoleucyl tRNA synthetase enzyme. High-level resistance in staphylococci has been shown to be due to a distinct, plasmid encoded isoleucyl tRNA synthetase enzyme.

Intrinsic resistance in Gram negative organisms such as the Enterobacteriaceae could be due to poor penetration of the outer membrane of the Gram-negative bacterial cell wall.

Due to its particular mode of action, and its unique chemical structure, mupirocin does not show any cross-resistance with other clinically available antibiotics.

#### Therapeutic Indication:

Bacterial skin infections, particularly those caused by Gram-positive organisms (except pseudomonal infection)

#### Posology and method of administration

TO THE SKIN

Child: Apply up to 3 times a day for up to 10 days

Adult: Apply up to 3 times a day for up to 10 days

#### Contraindications:

Hypersensitivity to the active substance(s) or to any of the excipients.

This Mupirocin Ointment formulation is not suitable for ophthalmic or intranasal use

#### Side effects

Burning sensation, local reactions, pruritus, rash, Urticarial.

#### Pregnancy

Manufacturer advises avoid unless potential benefit outweighs risk—no information available.

#### Renal Impairment

Manufacturer advises caution when mupirocin ointment used in moderate or severe Impairment because it contains macrogols (polyethylene glycol).

#### Brest feeding

No information available.

#### Special warnings and precautions for use:

Should a possible sensitisation reaction or severe local irritation occur with the use of Mupirocin Ointment, treatment should be discontinued, the product should be washed off and appropriate therapy instituted.

As with other antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms. Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. Although this is less likely to occur with topically applied mupirocin, if prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.

#### Mupirocin Ointment is not suitable for:

- Ophthalmic use;
  - Intranasal use (in neonates or infants);
  - Use in conjunction with cannulae;
  - At the site of central venous cannulation.
- Avoid contact with the eyes. If contaminated, the eyes should be thoroughly irrigated with water until the ointment residues have been removed.

#### Over dosage:

#### Symptoms

There is currently limited experience with over dosage of mupirocin.

#### Management

The toxicity of mupirocin is very low. In the event of accidental ingestion of the ointment, symptomatic treatment should be given.

In case of erroneous oral intake of large quantities of the ointment, renal function should be closely monitored in patients with renal insufficiency because of the possible side effects of polyethylene glycol.

There is no specific treatment for an overdose of mupirocin. In the event of overdose, the patient should be treated supportively with appropriate monitoring as necessary. Further management should be as clinically indicated or as recommended by the national poisons centre, where available.

#### Storage:

Store below 30°C. Protect from light.

**Presentation:** 15 gm Aluminium Collapsible Tube

NAFDAC Reg. No.:



Manufactured in India by:

**Ciron Drugs**

& Pharmaceuticals Pvt. Ltd.

N-118, 119, 113, 119/1, 119/2

& 118/1, M.I.D.C., Tarapur,

Boisar, Dist. Palghar - 401 506.

www.cironpharma.com

(Previously part of District Thane)



Manufactured for:

**CHEZ RESOURCES**

PHARMA NIG LTD

No 7 Calabar Street,

Fegge Onisha,

Anambra state, Nigeria

130 mm